Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Nature Reviews Clinical Oncology, Published online: 21 April 2023; doi:10.1038/s41571-023-00756-zAntibody–drug conjugates (ADCs) have demonstrated efficacy in patients with various cancers, although their antitumour activity in the central nervous system (CNS) might be limited by the blood–brain barrier. In this Review, the authors describe the available clinical data emphasizing the heterogeneous activity of ADCs against primary or secondary brain tumours and ongoing clinical trials in this area. In addition, they discuss physical, biological and molecular determinants of the CNS activity of ADCs, as well as potential strategies to improve delivery of these agents to brain tumours.

Source: Nature Reviews Clinical Oncology - April 21, 2023 Category: Cancer & Oncology Authors: Maximilian J. Mair Rupert Bartsch Emilie Le Rhun Anna S. Berghoff Priscilla K. Brastianos Javier Cortes Hui K. Gan Nancy U. Lin Andrew B. Lassman Patrick Y. Wen Michael Weller Martin van den Bent Matthias Preusser Source Type: research